MAINZ, Germany—The chief executive of the German company partnering with Pfizer Inc. in its coronavirus vaccine effort said the two are racing to increase production to meet the world’s needs, assuming the shot wins a regulatory green light.
The two companies are now scrambling to scale up their manufacturing capacities, said Ugur Sahin, CEO of BioNTech SE. Both companies said they are confident they will be able to deliver all the doses they have already agreed to provide to governments, including the U.S. and the European Union.
BioNTech and Pfizer are among a handful of companies in advanced stages of testing their vaccine. They committed to supplying over 450 million doses this year and next year, contingent on late-stage trials showing the vaccine to be safe and effective, and governments give the go-ahead for its use.
The U.S. government placed an initial order of 100 million doses, with the option to purchase 500 million additional doses. The EU ordered 200 million doses with an option for another 100 million. The government of Japan ordered 120 million doses, and Britain ordered 30 million.
All orders are subject to regulatory approval, and only the price of the U.S. deal—$1.95 billion—has been disclosed so far.
................der Rest kostenpflichtig |
Thread abonnieren
